{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:49:09Z","timestamp":1784332149581,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10620-024-08589-1","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:36:56Z","timestamp":1724420216000},"page":"3116-3118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tofacitinib in Ulcerative Colitis \u2013 Second-Line Therapy, First-Rate Results"],"prefix":"10.1007","volume":"69","author":[{"given":"Sidharth","family":"Harindranath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"8589_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s44197-023-00145-w","volume":"13","author":"X Chen","year":"2023","unstructured":"Chen X, Xiang X, Xia W et al. Evolving trends and burden of inflammatory bowel disease in Asia, 1990\u20132019: a comprehensive analysis based on the global burden of disease study. J Epidemiol Glob Health. 2023;13:725\u2013739.","journal-title":"J Epidemiol Glob Health."},{"key":"8589_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5217\/ir.2021.00115","volume":"20","author":"SH Park","year":"2022","unstructured":"Park SH. Update on the epidemiology of inflammatory bowel disease in Asia: where are we now? Intest Res. 2022;20:159\u2013164.","journal-title":"Intest Res."},{"key":"8589_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.dld.2023.11.022","volume":"56","author":"S Vieujean","year":"2024","unstructured":"Vieujean S, Laharie D, Buisson A et al. Histological healing induced by tofacitinib in ulcerative colitis: a multicentre study. Dig Liver Dis. 2024;56:613\u2013621.","journal-title":"Dig Liver Dis."},{"key":"8589_CR4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s10620-024-08394-w","volume":"69","author":"AM Carvalhas Gabrielli","year":"2024","unstructured":"Carvalhas Gabrielli AM, Ferretti F, Monico CM et al. Effect of tofacitinib on one-year colectomy risk in anti-TNF refractory ulcerative colitis: a prospective multicenter italian study. Dig Dis Sci 2024;69:1785\u20131792. https:\/\/doi.org\/10.1007\/s10620-024-08394-w.","journal-title":"Dig Dis Sci"},{"key":"8589_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","volume":"8","author":"M Fumery","year":"2014","unstructured":"Fumery M, Xiaocang C, Dauchet L et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2014;8:469\u2013479.","journal-title":"J Crohns Colitis."},{"key":"8589_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.dld.2019.10.003","volume":"52","author":"L Lair-Mehiri","year":"2020","unstructured":"Lair-Mehiri L, Stefanescu C, Vaysse T et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020;52:268\u2013273.","journal-title":"Dig Liver Dis."},{"key":"8589_CR7","doi-asserted-by":"crossref","unstructured":"Deepak, P. et al. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clinical Gastroenterology and Hepatology 2021, 19.","DOI":"10.1016\/j.cgh.2020.06.050"},{"key":"8589_CR8","doi-asserted-by":"crossref","unstructured":"Berinstein, J.A. et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: A retrospective case-control study\u2019, Clinical Gastroenterology and Hepatology 2020, 19.","DOI":"10.1016\/j.cgh.2021.05.038"},{"key":"8589_CR9","unstructured":"Rubin DT, Salese L, Cohen M et al. Presence of risk factors associated with colectomy among patients with ulcerative colitis: a post hoc analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program. Therapeutic Adv Gastroenterol."},{"key":"8589_CR10","doi-asserted-by":"crossref","unstructured":"Turner D, Ricciuto A, Lewis A et al. International organization for the study of IBD. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021: 160:1570\u20131583","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"8589_CR11","unstructured":"Ulcerative colitis: Clinical trial endpoints 2016. Available at: https:\/\/www.fda.gov\/files\/drugs\/published\/Ulcerative-Colitis--Clinical-Trial-Endpoints-Guidance-for-Industry.pdf (Accessed: 11 June 2024)."},{"key":"8589_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28:32\u201340.","journal-title":"Inflamm Bowel Dis."},{"key":"8589_CR13","doi-asserted-by":"crossref","unstructured":"Giri S, Bhrugumalla S, Kamuni A, et al. Upfront tofacitinib in patients with biological-na\u00efve ulcerative colitis - An Indian multicentric experience. Indian J Gastroenterol. 2023; Sep 20.","DOI":"10.1007\/s12664-023-01434-9"},{"key":"8589_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","volume":"18","author":"A Singh","year":"2024","unstructured":"Singh A, Midha V, Kaur K et al. Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis [ORCHID]: a prospective, open-label, randomized. Pilot Study. J Crohns Colitis. 2024;18:300\u2013307.","journal-title":"Pilot Study. J Crohns Colitis."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08589-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T20:31:56Z","timestamp":1726864316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08589-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["8589"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08589-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration number"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}